Patents Assigned to Board of Regents, The University of Texas
-
Patent number: 11981740Abstract: Provided herein are BAFF-R antibodies as well as compositions and methods of making and using the same. The antibodies provided herein are, inter alia, useful for the treatment of cancer and autoimmune diseases.Type: GrantFiled: August 16, 2021Date of Patent: May 14, 2024Assignees: CITY OF HOPE, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Hong Qin, Larry W. Kwak, Jingxing Li, Kexin Huang
-
Patent number: 11981736Abstract: Antibodies that selectively bind to glycosylated PD-1 relative to unglycosylated PD-1 are provided. In some aspects, PD-1 polypeptides comprising glycosylated amino acid positions are also provided. Methods for making and using such antibodies and polypeptides (e.g., for the treatment of cancer) are also provided.Type: GrantFiled: November 13, 2020Date of Patent: May 14, 2024Assignees: ST CUBE INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Stephen S. Yoo, Ezra M. Chung, Yong-Soo Kim, Seung-Oe Lim, Chia-Wei Li, Mien-Chie Hung
-
Patent number: 11981662Abstract: The inventors have used a differential nuclear staining (DNS) assay to discover compounds with cytotoxic activity against the CEM cell line that has been determined to be highly sensitive to a variety of anti-cancer compounds. Compounds were synthesized based on a pyrazole backbone structure. Several newly synthesized compounds have been tested to identify the compounds with highest activity. One compound identified is the SSK-3 compound which has been tested on cancer cell lines and determined that it induced apoptosis via phosphatidylserine membrane exposure and activation of caspase 3 in the CEM lymphoma cell line.Type: GrantFiled: October 12, 2022Date of Patent: May 14, 2024Assignees: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Renato J. Aguilera, Subhas S. Karki, Sujeet Kumar, Manuel L. Penichet
-
Patent number: 11980634Abstract: Methods of reconstituting lyophilized Annamycin and methods of treating patients are described.Type: GrantFiled: October 5, 2023Date of Patent: May 14, 2024Assignees: Moleculin Biotech, Inc., Board of Regents, The University of Texas SystemInventors: Donald Picker, Waldemar Priebe
-
Publication number: 20240150848Abstract: Aspects of the disclosure are directed to methods and systems for diagnosis, classification, and treatment of small cell lung cancer and high grade neuroendocrine carcinomas. Certain aspects comprise detection and analysis of tumor DNA methylation. Included in the disclosure are methods for identifying a subject as having a particular small cell lung cancer subtype based on DNA N methylation analysis, as well as methods and compositions for treatment of a subject based on subtype classification.Type: ApplicationFiled: March 3, 2022Publication date: May 9, 2024Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: John V. HEYMACH, Simon HEEKE, Lauren A. Byers, Carl M. GAY
-
Publication number: 20240150836Abstract: The present disclosure generally relates to compositions and methods for predicting or diagnosing immune-related adverse events (irAE) before, during, or after immune checkpoint inhibitor (ICI) treatment in a subject with cancer. The method includes assessment of transcripts, autoantibody levels, cytokine levels, and immune cells. The irAE can be ICI-related myositis, ICI-related myocarditis or ICI-related myositis and myocarditis.Type: ApplicationFiled: November 8, 2023Publication date: May 9, 2024Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Jason Y. Park, John David Farrar, David E. Gerber, Farjana Fattah, Hong Mu-Mosley
-
Publication number: 20240150752Abstract: Disclosures herein are directed to methods and compositions for the detection of and screening for mutations that convey phenotypic properties in a protein such as, for example, drug-resistance. Embodiments of the present disclosure include lentiviral-based compositions for transferring a gene encoding a protein of interest into a target cell for screening according to methods disclosed herein.Type: ApplicationFiled: March 8, 2022Publication date: May 9, 2024Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Ralf KITTLER, John D. MINNA, Paul M. YENERALL
-
Publication number: 20240148666Abstract: The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.Type: ApplicationFiled: December 11, 2023Publication date: May 9, 2024Applicant: The Board of Regents of The University of Texas SystemInventors: Qiang CHENG, Tuo WEI, Daniel J. SIEGWART
-
Publication number: 20240153091Abstract: Some methods comprise, for each of one or more lesions of a patients brain, from data taken at first and second times, determining two or more lesion characteristics including a lesion's volume change and whether the lesion moved toward a center of the brain. Some methods comprise, for each lesion, determining whether one or more criteria are satisfied, including a volume-and-displacement-based criterion that is satisfied when the change in the volume of the lesion is less than zero and the lesion moved toward the brain's center or the change in the volume of the lesion is greater than zero and the lesion did not move toward the brain's center. Some methods comprise characterizing whether the patient has multiple sclerosis and/or the progression, regression, or stability of multiple sclerosis based at least in part on the assessment of the one or more criteria for each of the lesion(s).Type: ApplicationFiled: March 8, 2022Publication date: May 9, 2024Applicant: The Board of Regents of The University of Texas SystemInventor: Darin T. OKUDA
-
Patent number: 11977970Abstract: The present disclosure provides a domain wall magnetic tunnel junction device. Integration of input spikes pushes a domain wall within a ferromagnetic track toward a magnetic tunnel junction (MTJ). An energy gradient within the track pushes the domain wall away from the MTJ by leaking accumulated energy from the input spikes. If the integrated input spikes exceed the energy leak of the gradient within a specified time period, the domain wall reaches the MTJ and reverses its resistance, producing an output spike. The leaking energy gradient can be created by a magnetic field, a trapezoidal shape of the ferromagnetic track, or nonuniform material properties in the ferromagnetic track. A feedback and feedforward crossbar configuration is disclosed that provides for a neuromorphic computing system suitable for unsupervised learning.Type: GrantFiled: March 24, 2021Date of Patent: May 7, 2024Assignee: Board of Regents, The University of Texas SystemInventors: Joseph S. Friedman, Wesley H. Brigner, Naimul Hassan, Xuan Hu, Alvaro Velasquez
-
Patent number: 11976128Abstract: The present disclosure is directed to antibodies binding to PD-L2 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L2.Type: GrantFiled: March 15, 2019Date of Patent: May 7, 2024Assignee: Board of Regents, The University of Texas SystemInventors: Michael A. Curran, Ashvin R. Jaiswal, Dongxing Zha, Kui Voo, Carlo Toniatti, Bianka Prinz, Nadthakarn Boland
-
Publication number: 20240141330Abstract: Disclosures herein are directed to methods and compositions for the detection of and screening for mutations that convey phenotypic properties in a protein such as, for example, drug-resistance. Embodiments of the present disclosure include lentiviral-based compositions for enhanced mutagenesis and screening of genes encoding proteins of interest that confer drug resistance according to methods disclosed herein.Type: ApplicationFiled: January 10, 2024Publication date: May 2, 2024Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Ralf KITTLER, John D. MINNA, Paul M. YENERALL
-
Publication number: 20240141348Abstract: Provided herein are compositions and methods for reducing expression of C9orf72 transcripts in cells containing expanded intronic GGGGCC regions, including those in subjects having or at risk of developing amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).Type: ApplicationFiled: October 19, 2023Publication date: May 2, 2024Applicant: The Board of Regents of The University of Texas SystemInventors: David COREY, Jiaxin HU
-
Publication number: 20240141350Abstract: Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.Type: ApplicationFiled: November 30, 2023Publication date: May 2, 2024Applicants: Regulus Therapeutics Inc., The Board of Regents of The University of Texas SystemInventors: Charles R. ALLERSON, Vishal D. PATEL, B. Nelson CHAU, John R. ANDROSAVICH
-
Publication number: 20240140994Abstract: Provided herein are engineered hMPV F proteins. In some aspects, the engineered F proteins exhibit enhanced conformational stability and/or antigenicity. Methods are also provided for use of the engineered F proteins as diagnostics, in screening platforms, and/or in vaccine compositions.Type: ApplicationFiled: January 12, 2024Publication date: May 2, 2024Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Jason MCLELLAN, Ching-Lin HSIEH, Scott RUSH, Nianshuang WANG
-
Patent number: 11969182Abstract: Provided herein is a surgical instrument comprising a cap having a first and second aperture extending therethrough, a first extendable and retractable member having a distal end coupled to a first coupling, a first arm extending from the first coupling and pivotable with respect to the distal end of the first member, and a second arm connected to the first arm through a second coupling and pivotable, with respect to the first arm, a second extendable and retractable member having a distal end coupled to a third coupling, a third arm extending from the second coupling, the third arm pivotable, with respect to the distal end of the second member, and a fourth arm connected to the third arm through a fourth coupling and pivotable, with respect to the third arm, a first end effector connected to the second arm and a second end effector connected to the fourth arm.Type: GrantFiled: September 4, 2020Date of Patent: April 30, 2024Assignees: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, ColubrisMX, IncInventors: Daniel H. Kim, Dong Suk Shin, Taeho Jang, Yongman Park, Jeihan Lee, Hongmin Kim, Kihoon Nam, Seokyung Han
-
Patent number: 11969387Abstract: The present invention includes an intraoral tool, including one or more selected solid or inflatable inserts targeted to provide a low load prolonged stretch to orofacial musculature that may be coupled to tool handle or tool mounting bracket, wherein the intraoral tool is configured for a delivery of intraoral treatment, such as a stretch to a patient's facial injury or disorder and configured to permit manipulation of the insert in the patient's mouth.Type: GrantFiled: January 4, 2019Date of Patent: April 30, 2024Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Lori Arguello, Kathleen Kerr
-
Patent number: 11970534Abstract: Provided herein are molecules having an antigen binding fragment that immunospecifically binds to BTN1A1, such as anti-BTN1A1 antibodies. These molecules include those having an antigen binding fragment that immunospecifically binds to glycosylated BTN1A1, such as anti-glycosylated BTN1A1 antibodies. Methods of making and using these molecules are also provided, including methods of using them in cancer therapies, or as cancer diagnostics.Type: GrantFiled: November 24, 2020Date of Patent: April 30, 2024Assignees: STCUBE & CO., INC., Board of Regents, The University of Texas SystemInventors: Stephen Sunghan Yoo, Michael Joseph Surace, Steven Hsesheng Lin, Amrish Sharma
-
Patent number: 11973441Abstract: A microelectromechanical (MEMS) device is provided. The MEMS device comprises a substrate and a movable structure flexurally connected to the substrate, capable of moving in relation to the substrate, wherein the movable structure further comprising two or more segments having at least one mechanical connection between said segments to provide structural integrity of the moving structure; and wherein the at least one mechanical connection electrically isolates at least two segments.Type: GrantFiled: December 20, 2021Date of Patent: April 30, 2024Assignee: Board of Regents, The University of Texas SystemInventors: Seyed Omid Reza Moheimani, Afshin Alipour, Mustafa Bulut Coskun
-
Patent number: 11969522Abstract: The present disclosure describes the use of immune modulators to promote nerve growth and regeneration, particularly in the context of nerve deficit stemming from trauma and disease. In particular, the disclosure provides for the use of CXCR4 antagonsists, STAT3 activators, and an agent that increase nitric oxide, alone or in combination, to treat nerve deficit conditions.Type: GrantFiled: July 7, 2020Date of Patent: April 30, 2024Assignees: The Board of Regents of the University of Texas SystemInventors: Jonathan Cheng, Edward Keefer, Srikanth Vasudevan